Ryvu Therapeutics SA
WSE:RVU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Ryvu Therapeutics SA
Depreciation & Amortization
Ryvu Therapeutics SA
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
R
|
Ryvu Therapeutics SA
WSE:RVU
|
Depreciation & Amortization
zł9.9m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
11%
|
|
|
N
|
Nanogroup SA
WSE:NNG
|
Depreciation & Amortization
zł75.9k
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
M
|
Medicofarma Biotech SA
WSE:MDB
|
Depreciation & Amortization
zł1.5m
|
CAGR 3-Years
18%
|
CAGR 5-Years
81%
|
CAGR 10-Years
N/A
|
|
|
S
|
Selvita SA
WSE:SLV
|
Depreciation & Amortization
zł54.8m
|
CAGR 3-Years
13%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
Ryvu Therapeutics SA
Glance View
Ryvu Therapeutics SA engages in the provision of products and solutions for the pharmaceutical and biotechnology industry. The company is headquartered in Krakow, Woj. Malopolskie and currently employs 186 full-time employees. The company went IPO on 2011-07-14. The firm is active in the pharmaceutical and biotechnology fields. The company operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. The company operates through unit Ardigen SA and SORS Holdings Ltd.
See Also
What is Ryvu Therapeutics SA's Depreciation & Amortization?
Depreciation & Amortization
9.9m
PLN
Based on the financial report for Dec 31, 2025, Ryvu Therapeutics SA's Depreciation & Amortization amounts to 9.9m PLN.
What is Ryvu Therapeutics SA's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
11%
Over the last year, the Depreciation & Amortization growth was -6%. The average annual Depreciation & Amortization growth rates for Ryvu Therapeutics SA have been -9% over the past three years , -4% over the past five years , and 11% over the past ten years .
